Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload
出版年份 2020 全文链接
标题
Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload
作者
关键词
-
出版物
CARDIOVASCULAR DRUGS AND THERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-19
DOI
10.1007/s10557-020-06989-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Blockade of MCU-Mediated Ca2+ Uptake Perturbs Lipid Metabolism via PP4-Dependent AMPK Dephosphorylation
- (2019) Dhanendra Tomar et al. Cell Reports
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Altered mitochondrial metabolism in the insulin‐resistant heart
- (2019) Marina Makrecka‐Kuka et al. Acta Physiologica
- Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure
- (2019) Hideo Nambu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction
- (2018) Natasha Fillmore et al. MOLECULAR MEDICINE
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
- (2018) Aysegul Durak et al. Cardiovascular Diabetology
- Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
- (2018) Yumei Ye et al. CARDIOVASCULAR DRUGS AND THERAPY
- Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
- (2017) Ioanna Andreadou et al. Frontiers in Physiology
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance
- (2016) Edgars Liepinsh et al. PHARMACOLOGICAL RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now